Use of Clobazam for Epilepsy and Anxiety
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03371836|
Recruitment Status : Completed
First Posted : December 13, 2017
Results First Posted : March 4, 2021
Last Update Posted : March 4, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy Anxiety||Drug: Clobazam||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||All participants receive treatment and outcome is assessed; there is no control group.|
|Masking:||None (Open Label)|
|Official Title:||Use of Clobazam in Treating Anxiety Comorbid With Pediatric Epilepsy|
|Actual Study Start Date :||October 1, 2017|
|Actual Primary Completion Date :||December 31, 2019|
|Actual Study Completion Date :||December 31, 2019|
open label (single treatment arm)
Clobazam is used as an adjunct medicine for all participants.
Other Name: Onfi
- CGI-I [ Time Frame: 14-18 weeks ]Mean of Clinical Global Impression-Improvement from baseline. (1-7 point scale; lower score equals a better outcome; 1 is the maximum improvement, 7 is the minimum improvement)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||6 Years to 17 Years (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Established diagnosis of epilepsy, characterized by focal seizures with suspected or documented localization in the temporal lobe. All participants will have active epilepsy that requires treatment with anticonvulsant medication.
- Although it is not necessary to be seizure free, a seizure baseline period will be established in the 60 days prior to enrollment into the study.
- Current regimen of anticonvulsant drugs must have been stable for 30 days prior to entry into the study.
- No episodes of seizure clusters of status epilepticus within 30 days prior to entry into the study.
- Established symptoms of anxiety with functional impairment.
- A diagnosis of an anxiety disorder based on the administration of the K-SADS Male or female participants equal to or above age 6 and below age 18 at the start of the study. No exclusion will be made on the basis of gender or minority status.
- Male or female participants equal to or above age 6 and below age 18 at the start of the study. No exclusion will be made on the basis of gender or minority status.
- Good general health as determined by medical history and physical examination.
- Ability to swallow pills (participant will receive pill swallowing instruction if necessary). The medicine may be cut into pieces and/or mixed with applesauce.
- If female of childbearing age, a negative urine or serum pregnancy test must be established or assured at baseline. Additionally, the participant must agree to use abstinence or appropriate contraception methods or be otherwise incapable of pregnancy for the duration of the study. Pregnancy test results will be shared with parent or guardian. Pregnancy status (or prevention) and abstinence or contraception methods will be addressed throughout the study for females of childbearing age as well as for post-pubertal males.
- Previous subjects who failed at any point to meet continuation criteria and withdrew early may be considered for re-enrollment by the PI on a case-by-case basis.
- Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.
- Previous allergic or hypersensitivity reactions to Onfi® or benzodiazepines
- Active substance abuse or dependence within 30 days of enrollment
- DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.
- Current standing use of benzodiazepines (except as "rescue" medicine)
- Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.
- Participation in a previous experimental drug study within 30 days of baseline visit.
- Estimated IQ<70 as indicated by initial clinical assessment (rendering rating scales invalid)
- Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03371836
|United States, Maryland|
|Kennedy Krieger Institute|
|Baltimore, Maryland, United States, 21205|
|Principal Investigator:||Jay Salpekar, MD||KKI/JH|
Documents provided by Jay Salpekar, M.D., Hugo W. Moser Research Institute at Kennedy Krieger, Inc.:
|Responsible Party:||Jay Salpekar, M.D., Principal Investigator, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|
|Other Study ID Numbers:||
|First Posted:||December 13, 2017 Key Record Dates|
|Results First Posted:||March 4, 2021|
|Last Update Posted:||March 4, 2021|
|Last Verified:||February 2021|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
Molecular Mechanisms of Pharmacological Action